Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04197219
Title Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
Recruitment Withdrawn
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Haider Mahdi

endometrial mixed adenocarcinoma

endometrial cancer

endometrial clear cell adenocarcinoma


Axitinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST